SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock Quote

SHPH [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	63.42%	Shs Outstand	13.28M	Perf Week	-
Market Cap	483.51M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.86M	Perf Month	-
Income	-	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	-	Perf Half Y	-
Book/sh	-0.25	P/B	-	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	11.77 - 126.26	Perf YTD	-5.41%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-65.31%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	272.13%	ATR	48.27
Employees	5	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	-	Volatility	- -
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	1.56	Prev Close	36.40
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	7.11M	Price	43.80
Recom	-	SMA20	28.31%	SMA50	28.31%	SMA200	28.31%	Volume	1,719,144	Change	20.33%

Sep-06-22 09:00AM	Shuttle Pharmaceuticals Announces Closing of Initial Public Offering PR Newswire +91.28%
Aug-31-22 01:20PM	Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH" PR Newswire
Aug-30-22 04:40PM	Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering PR Newswire

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience